Lifesci Capital Issues Pessimistic Outlook for RAPT Earnings

Rapt Therapeutics (NASDAQ:RAPT) – Investment analysts at Lifesci Capital decreased their FY2026 earnings estimates for Rapt Therapeutics in a report issued on Monday, October 20th. Lifesci Capital analyst S. Slutsky now forecasts that the company will post earnings of ($1.60) per share for the year, down from their previous estimate of ($1.58). Lifesci Capital has a “Strong-Buy” rating and a $31.00 price target on the stock. The consensus estimate for Rapt Therapeutics’ current full-year earnings is ($2.14) per share.

RAPT has been the topic of several other research reports. Wells Fargo & Company restated an “overweight” rating and issued a $48.00 price target (up previously from $38.00) on shares of Rapt Therapeutics in a research report on Tuesday. Zacks Research lowered shares of Rapt Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, August 22nd. JPMorgan Chase & Co. raised shares of Rapt Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $13.00 to $55.00 in a research note on Monday. HC Wainwright lifted their price objective on shares of Rapt Therapeutics to $27.00 and gave the stock a “buy” rating in a research note on Thursday, July 10th. Finally, Barclays lifted their price objective on shares of Rapt Therapeutics from $35.00 to $58.00 and gave the stock an “overweight” rating in a research note on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $33.00.

Rapt Therapeutics Stock Performance

Shares of RAPT opened at $30.00 on Thursday. The company’s fifty day moving average is $19.90 and its 200 day moving average is $12.40. Rapt Therapeutics has a fifty-two week low of $5.67 and a fifty-two week high of $42.39. The stock has a market capitalization of $496.20 million, a PE ratio of -2.12 and a beta of 0.23.

Rapt Therapeutics (NASDAQ:RAPT) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.04).

Institutional Trading of Rapt Therapeutics

A number of large investors have recently made changes to their positions in the stock. Callan Family Office LLC lifted its stake in Rapt Therapeutics by 53.9% in the first quarter. Callan Family Office LLC now owns 89,327 shares of the company’s stock worth $109,000 after acquiring an additional 31,287 shares during the period. Comerica Bank lifted its stake in Rapt Therapeutics by 53.9% in the first quarter. Comerica Bank now owns 89,327 shares of the company’s stock worth $109,000 after acquiring an additional 31,287 shares during the period. Invesco Ltd. lifted its stake in Rapt Therapeutics by 411.7% in the first quarter. Invesco Ltd. now owns 58,901 shares of the company’s stock worth $72,000 after acquiring an additional 47,391 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Rapt Therapeutics by 112.7% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 150,946 shares of the company’s stock worth $184,000 after purchasing an additional 79,967 shares during the last quarter. Finally, Checkpoint Capital L.P. purchased a new stake in shares of Rapt Therapeutics during the 1st quarter worth $134,000. 99.09% of the stock is owned by hedge funds and other institutional investors.

About Rapt Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.